Table 2.
General use | Health-related use | |||
---|---|---|---|---|
% a | PR (95% CI) b | % a | PR (95% CI) b | |
Overall | 60 | 43 | ||
Sex | ||||
Male | 62 | Reference | 46 | Reference |
Female | 57 | 0.91 (0.71-1.15) | 38 | 0.83 (0.6-1.14) |
Age, y | ||||
<50 | 88 | Reference | 74 | Reference |
50-64 | 69 | 0.79 (0.64-0.96) c | 57 | 0.77 (0.57-1.05) |
65-79 | 56 | 0.63 (0.5-0.8) d | 31 | 0.42 (0.28-0.62) d |
≥80 | 30 | 0.34 (0.22-0.55) d | 20 | 0.28 (0.15-0.5) d |
Race | ||||
White | 70 | Reference | 46 | Reference |
Other race | 67 | 0.83 (0.61-1.13) | 33 | 0.71 (0.44-1.14) |
Cancer site | ||||
Oral cavity | 74 | Reference | 54 | Reference |
Pharynx | 61 | 0.82 (0.67-1.02) | 43 | 0.79 (0.58-1.08) |
Larynx | 44 | 0.6 (0.4-0.9) c | 31 | 0.57 (0.34-0.98) c |
Education | ||||
Master | 96 | Reference | 84 | Reference |
Bachelor | 79 | 0.82 (0.62-1.08) c | 61 | 0.84 (0.49-1.04) |
Some college | 75 | 0.78 (0.66-0.92) e | 53 | 0.63 (0.48-0.85) e |
High school | 51 | 0.54 (0.42-0.69) d | 31 | 0.36 (0.24-0.55) d |
<High school | 17 | 0.18 (0.09-0.35) d | 11 | 0.13 (0.06-0.30) d |
Income as % FPL | ||||
≥400 | 78 | Reference | 61 | Reference |
300 to <400 | 67 | 0.86 (0.64-1.15) | 36 | 0.59 (0.33-1.07) |
200 to <300 | 56 | 0.71 (0.48-1.04) | 26 | 0.42 (0.23-0.77) e |
100 to <200 | 40 | 0.51 (0.36-0.74) d | 32 | 0.52 (0.34-0.81) e |
<100 | 36 | 0.46 (0.27-0.8) e | 29 | 0.47 (0.24-0.92) c |
Region | ||||
Northeast | 57 | Reference | 44 | Reference |
Midwest | 61 | 1.06 (0.72-1.57) | 38 | 0.87 (0.52-1.48) |
South | 57 | 0.99 (0.7-1.41) | 42 | 0.96 (0.61-1.51) |
West | 72 | 1.25 (0.88-1.7) | 50 | 1.15 (0.72-1.83) |
Health insurance | ||||
Public | 50 | Reference | 33 | Reference |
Private | 70 | 1.37 (1.1-1.7) e | 51 | 1.53 (1.01-2.02) c |
Abbreviations: FPL, federal poverty level; PR, prevalence ratio.
Weighted percentages.
Univariate robust Poisson regression.
P < .05.
P < .001.
P < .01.